Skip to main content
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. — Investor Relations & Filings

Ticker · ROIV ISIN · BMG762791017 LEI · 549300DL466NY5J6U724 US Manufacturing
Open in API
Filings indexed 862 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country BM Bermuda
Listing US ROIV

About Roivant Sciences Ltd.

http://roivant.com/

Roivant Sciences is a biopharmaceutical company that develops and commercializes medicines and technologies. The company operates a unique model by building agile, focused subsidiary companies known as 'Vants' to advance specific assets. This structure is designed to accelerate the discovery, development, and delivery of innovative treatments to patients through efficient capital allocation and execution. Roivant employs technology, including artificial intelligence for drug discovery and protein design, across its operations. The company's portfolio spans multiple therapeutic areas, such as autoimmune and pulmonary diseases, and includes commercial-stage products like Vtama for psoriasis and atopic dermatitis, alongside a broad pipeline of investigational drugs.

Recent filings

Filing Released Lang Actions
FORM S-8
Regulatory Filings Classification · 85% confidence The document is an SEC Form S-8 Registration Statement under the Securities Act of 1933, registering additional shares of common stock for an employee equity incentive plan. It does not contain financial results (10-K, IR, ER), board changes (MANG), M&A, or other specific transaction news. It is a compliance/regulatory filing that does not fit any more specific category, so it falls under the general Regulatory Filings category (RNS).
2026-05-20 English
10-K
Annual Report FY 2026
2026-05-20 English
8-K
Report Publication Announcement Classification · 85% confidence The document is an SEC Form 8-K current report that does not include financial statements itself but instead announces that a press release with the Q4 and fiscal year financial results (Exhibit 99.1) has been issued and attached. This matches the definition of a Report Publication Announcement (RPA) under the “menu vs meal” rule, as it simply notifies investors of the release and attaches the report rather than containing substantive financial data.
2026-05-20 English
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes preliminary unaudited financial information for the quarter ended March 31, 2026, including cash and marketable securities and share repurchases. It also references a press release about clinical program updates and topline results from clinical studies. The document explicitly states that the financial information is preliminary and unaudited, and the audit is ongoing. There are no comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). The document is primarily an announcement of recent events and preliminary results, consistent with the purpose of an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2026-04-02 English
SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
Director's Dealing
2026-03-25 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.